FDA Revokes Emergency Kidney Drugs as COVID Era Fades
Published Date: 5/21/2025
Notice
Summary
The FDA has officially ended the emergency use permissions for certain kidney treatment products from Fresenius and Baxter as of January 16, 2025. This means these products can no longer be used under emergency rules, affecting hospitals and patients relying on them during COVID-19. The change helps ensure only fully approved treatments are used, with no extra costs announced.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Emergency Use Authorizations Revoked
On January 16, 2025, the FDA revoked the Emergency Use Authorizations for Fresenius Medical Care North America’s multiFiltrate PRO System and multiBic/multiPlus solutions (EUA 048) and Baxter Healthcare Corp.’s REGIOCIT (EUA 068). This means those products can no longer be used under emergency rules and the change affects hospitals and patients who were relying on them during the COVID-19 pandemic; the notice also states the change helps ensure only fully approved treatments are used and that no extra costs were announced.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2025-09063, Agency Information Collection Activities: Proposed Request and Comment Request
The Social Security Administration wants your feedback on some forms they use to collect info, especially about sharing personal records. They’re updating these forms and want to make them easier and less time-consuming for everyone. If you have thoughts, send them in by July 21, 2025, so your voice counts before changes take effect.
Next: 2025-09067, Product-Specific Guidance on Fluticasone Propionate; Draft Guidance for Industry; Availability
The FDA just released a draft guide to help drug makers test fluticasone propionate nasal sprays, making it easier to prove their products work the same as brand-name versions. This affects companies planning to submit generic drug applications and could speed up getting affordable options to market. Keep an eye out for final rules soon, which might save time and money in drug approvals!